Fibroheal Woundcare, a Bengaluru-based startup specializing in silk protein-based medical devices, has raised ₹6.3 crore in a pre-Series A funding round. The investment came from a mix of existing promoters and new investors, including surgeons, medical professionals, and bankers. Additionally, the company has secured commitments for an extra ₹10 crore from current and prospective investors.
The funds will be deployed to scale its go-to-market strategy, expand the team, and further develop its innovative product pipeline in the medical devices sector.
Founded in 2017 by Vivek Mishra and Bharat Tandon, Fibroheal has made significant inroads into the healthcare industry, with its products being used in over 500 hospitals across 19 states in India. The company has also ventured into online sales via multiple e-commerce platforms, increasing accessibility for its advanced wound care solutions.
Fibroheal’s product portfolio includes foams, mesh, and powders designed to treat a range of wound types, including acute, chronic, traumatic, post-operative, and hard-to-heal wounds such as bedsores and infected C-section scars.
The company has previously attracted funding from notable investors such as Telama Investments, CCAMP, and KITVEN. With this new infusion of capital, Fibroheal is poised to reinforce its position as a leader in the wound care segment and further its mission to revolutionize medical treatment through silk protein-based innovation.
